RECRUITINGOBSERVATIONAL
Bempedoic Acid Pregnancy Surveillance Program
A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During Pregnancy
About This Trial
Bempedoic acid pregnancy surveillance program
Who May Be Eligible (Plain English)
Who May Qualify:
Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome
Who Should NOT Join This Trial:
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome
Exclusion Criteria:
Treatments Being Tested
DRUG
Bempedoic Acid
Bempedoic Acid 180 MG
DRUG
Bempedoic Acid / Ezetimibe
Bempedoic Acid 180 MG / Ezetimibe 10 MG
Locations (1)
Evidera, PPD business unit
Morrisville, North Carolina, United States